Clinical Trials Logo
  1. Home
  2. Meningococcal Vaccine
  3. NCT04819113

Study to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age

Meningococcal Vaccine Clinical Trial

Official title:
A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE

Clinical Trial Summary

This study will evaluate the safety and immunogenicity of a single dose of Nimenrix in infants at 3 months of age, followed by a second dose at 12 months of age. Current posology allows for 2 doses of Nimenrix before 6 months of age, where the first dose is administered from 6 weeks onwards with a second dose at least 2 months later, with a booster at 12 months; and in infants from 6 months of age, a single dose at 6 months, with a booster dose at 12 months. This study will provide valuable immunogenicity and safety data for a single dose in healthy infants <6 months of age, followed by the booster at 12 months

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04819113
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 3
Start date April 9, 2021
Completion date September 9, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04645966 - A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants Phase 2
Completed NCT01299480 - A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years Phase 2
Completed NCT01323270 - A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. Phase 2
Completed NCT04440176 - A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules Phase 2
Completed NCT04440163 - MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age Phase 3
Completed NCT03509051 - Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation N/A
Completed NCT02975596 - MenB Vaccine: Implementation Via Information, Empowerment and Accessibility N/A
Completed NCT03263403 - Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh. Phase 2/Phase 3
Completed NCT04893811 - Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age Phase 4
Completed NCT03135834 - A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. Phase 3
Completed NCT01830855 - A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years Phase 3